**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Jessica Ammon, DO; Department of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA

**Main Body of the Abstract**
Our study aimed to increase suspicion for transthyretin amyloidosis (ATTR) among cardiologists leading to increased screening for amyloidosis.
Patients at risk for amyloidosis were retrospectively identified via chart review showing increased left ventricular wall thickness, intact systolic function, advanced age, and heart failure. A list of patients and instructions for ordering amyloidosis testing was given to cardiologists to determine if further evaluation was warranted. The number of Technetium 99m-Pyrophosphate (PYP) scans and ordering physicians before and after this intervention were recorded.
The algorithm identified 349 potential high-risk patients. 28 months prior to protocol initiation, PYP scans were ordered for 22 patients with 6 being equivocal or positive. During this project, 142 PYP scans were ordered, with 18 being equivocal or positive. The number of ordering providers increased from 7 prior to 22 by the end of this project within 24 months. Change point analysis noted on PYP scan ordering patterns noted a statistically significant difference in the total amount of PYP orders after protocol initiation (regression coefficient 1.27 vs 6.31, p<0.001), as well as the amount of equivocal or positive tests (regression coefficient 0.38 vs 0.52, p<0.01).
The results suggest that increasing awareness of patients at risk for ATTR increases the number of providers who screen, total number of PYP scans ordered, and identification of patients with equivocal or positive PYP scan results. Early and accurate diagnosis of ATTR is imperative as new therapies such as TTR silencers and TTR stabilizers can optimize cardiac function and symptom management.



Increasing clinicians’ suspicion of TTR amyloidosis using a retrospective algorithm PB92 (#559)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.